UA95497C2 - Antidiabetogenic calcium-peptide composition - Google Patents

Antidiabetogenic calcium-peptide composition

Info

Publication number
UA95497C2
UA95497C2 UAA200905665A UAA200905665A UA95497C2 UA 95497 C2 UA95497 C2 UA 95497C2 UA A200905665 A UAA200905665 A UA A200905665A UA A200905665 A UAA200905665 A UA A200905665A UA 95497 C2 UA95497 C2 UA 95497C2
Authority
UA
Ukraine
Prior art keywords
calcium
antidiabetogenic
peptide composition
diabetes
type
Prior art date
Application number
UAA200905665A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Марко Зелл
Дирк Боде
Гюнтер Завацки
Original Assignee
Гумана Милхунион Ег
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гумана Милхунион Ег filed Critical Гумана Милхунион Ег
Publication of UA95497C2 publication Critical patent/UA95497C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention relates to the use of a calcium-peptide composition obtained from at least one calcium salt, at least one caseinophosphopeptide (CPP), and/or at least one glycomacropeptide (GMP) for producing an agent for preventing and/or treating type II diabetes. Administering said composition makes it possible to significantly suppress the onset of type II diabetes (antidiabetogenic effect).
UAA200905665A 2006-11-06 2007-10-29 Antidiabetogenic calcium-peptide composition UA95497C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006052560A DE102006052560B4 (en) 2006-11-06 2006-11-06 Anti-diabetogenic calcium peptide composition

Publications (1)

Publication Number Publication Date
UA95497C2 true UA95497C2 (en) 2011-08-10

Family

ID=39148568

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200905665A UA95497C2 (en) 2006-11-06 2007-10-29 Antidiabetogenic calcium-peptide composition

Country Status (5)

Country Link
EP (1) EP2089046A2 (en)
DE (1) DE102006052560B4 (en)
EA (1) EA016545B1 (en)
UA (1) UA95497C2 (en)
WO (1) WO2008055801A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102378632A (en) 2009-04-03 2012-03-14 雀巢产品技术援助有限公司 Improvement in promotion of healthy catch-up growth
CN109846901A (en) * 2019-04-03 2019-06-07 江西安顺堂生物科技有限公司 It is a kind of to promote bone growth, anti-caries, the preparation and preparation process for supplementing calcium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL176042C (en) * 1978-11-13 1985-02-18 Cca Biochem B V METHOD FOR PREPARING AERIAL CONTAINERS FOR DIABETICIANS.
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
US6207638B1 (en) * 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
US6384087B1 (en) * 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
GB0100273D0 (en) * 2001-01-08 2001-02-14 Nestle Sa Nutritional composition for a bone condition
US20030165574A1 (en) * 2002-03-01 2003-09-04 Ward Loren Spencer Compositions and methods for treatment of body weight conditions
CN1395870A (en) * 2002-07-25 2003-02-12 徐佳立 Hypoglycemic health-care polypeptide food
KR100577677B1 (en) * 2003-06-25 2006-05-10 (주)현덕비엔티 Composition for lowering blood glucose
DE102005033630A1 (en) * 2005-07-19 2007-01-25 Humana Gmbh Calcium-peptide component

Also Published As

Publication number Publication date
DE102006052560A1 (en) 2008-05-08
EP2089046A2 (en) 2009-08-19
EA200970441A1 (en) 2009-12-30
EA016545B1 (en) 2012-05-30
WO2008055801A2 (en) 2008-05-15
WO2008055801A3 (en) 2008-12-04
DE102006052560B4 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
MX2009000657A (en) Compositions and methods for the treatment of mucositis.
TW200732296A (en) Novel compounds
MX2007002398A (en) New pharmaceutical compositions for the treatment of cancer.
WO2008097640A8 (en) Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
TW200745003A (en) Novel compounds
TW200612892A (en) Novel compounds
WO2009026179A3 (en) Antiinfective proanthocyanidin compounds and methods of use thereof
MX2007005590A (en) Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof.
WO2007139955A3 (en) Triazole compounds that modulate hsp90 activity
WO2007139967A3 (en) Triazole compounds that modulate hsp90 activity
JO2686B1 (en) compounds
TW200630336A (en) Novel compounds
MY150702A (en) Substituted 4-phenyltetrahydroisoquinonelines, method of producing them, their use as medicament, and also medicament containing them
TW200621690A (en) Novel compounds
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200731974A (en) Transdermal system for verenicline
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
TW200700071A (en) Novel use
CL2011000933A1 (en) The compound 2 - [(5-chloro-2 - {[3-methyl-1- (1-methyl ethyl) -1h-pyrazol-5-yl] amino} -4-pyridinyl) amino] -n- (methyloxy) benzamide and its salts, focal adhesion kinase inhibitor (fak); pharmaceutical composition that includes it; and its use for the treatment of cancer.
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2008073332A3 (en) Creatine compositions for skin treatment
TW200742580A (en) Methods for treating nephrolithiasis
CL2008003933A1 (en) Compounds derived from n-heterocyclo- [1,2-a] -pyridine-2-carboxamide; preparation procedure; pharmaceutical composition; Useful in the treatment and / or prevention of neurodegenerative and inflammatory diseases, epilepsy, osteoporosis, malignant tumors, among others.
HRP20080422T3 (en) Satraplatin for treating resistant or refractory tumors
UA95497C2 (en) Antidiabetogenic calcium-peptide composition